the care pathway to ensure rapid assessment and treatment for TIA patients would avoid 128 future stroke events over three years. As a result, the costs associated with the reconfiguration of the TIA patient care pathway would be partially offset by savings in acute stroke management costs. CONCLUSIONS: Our model suggests that implementing a revised TIA care pathway in Hungary would result in a reduction of TIA-related recurrent strokes, leading to reduced costs associated with the acute management of stroke. This would partially offset the costs of establishing rapid assessment and treatment clinics for patients experiencing TIA. OBJECTIVES: Preeclampsia, a leading cause of maternal and perinatal morbidity and mortality, is only detected after the onset of clinical symptoms. Earlier diagnosis may be possible with a new serum test using soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) biomarkers. Clinical and economic benefits may result from appropriate detection and management of subclinical cases, and from averting costs associated with incorrect diagnoses. We evaluated the financial impact of the novel test versus standard care from a UK health care payer perspective.
the care pathway to ensure rapid assessment and treatment for TIA patients would avoid 128 future stroke events over three years. As a result, the costs associated with the reconfiguration of the TIA patient care pathway would be partially offset by savings in acute stroke management costs. CONCLUSIONS: Our model suggests that implementing a revised TIA care pathway in Hungary would result in a reduction of TIA-related recurrent strokes, leading to reduced costs associated with the acute management of stroke. This would partially offset the costs of establishing rapid assessment and treatment clinics for patients experiencing TIA.
PCV53 FINANCIAL IMPACT OF A NOVEL PREECLAMPSIA DIAGNOSTIC TEST VS. STANDARD CARE: A DECISION-ANALYTIC MODELING ANALYSIS FROM A UK HEALTH CARE PAYER PERSPECTIVE
Hadker N 1 , Garg S 1 , Costanzo C 1 , Miller JD 1 , van der Helm W 2 , Foster T 1 , Creeden J 2 1 Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, 2 Roche Diagnostics, Ltd, Rotkreuz, Switzerland OBJECTIVES: Preeclampsia, a leading cause of maternal and perinatal morbidity and mortality, is only detected after the onset of clinical symptoms. Earlier diagnosis may be possible with a new serum test using soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) biomarkers. Clinical and economic benefits may result from appropriate detection and management of subclinical cases, and from averting costs associated with incorrect diagnoses. We evaluated the financial impact of the novel test versus standard care from a UK health care payer perspective. METHODS: We developed a decision-analytic model of the clinical and economic impact resulting from improved sensitivity and specificity of the new test over current diagnostic practice. Acute management and follow-up costs were associated with true positive, true negative, false positive, and false negative diagnoses. The basecase analysis assumed that, of all pregnant women, 15% present with risk factors while 85% do not. The CHF 52 (£-equivalent) test was assumed to be administered after 20 weeks of gestation. True positive and false negative patients were assumed to enter one of four health states: mild preeclampsia; severe preeclampsia; eclampsia; or death. Data pertaining to treatment practices, health care resource utilization, incidence, costs, and funding for detection and management of preeclampsia in the UK were obtained through interviews with clinicians, laboratory managers, and health care payers in the UK. Additional data were obtained from published literature and public databases. RESULTS: Model results suggest that when used for screening, the novel test would reduce false negative diagnoses of preeclampsia by 67% and false positives by 71%. Costs per patient are estimated to be £1781 with the novel test and £2726 with standard practice, saving an estimated £945 per patient given the novel test. CONCLUSIONS: This test has the potential to improve detection and management of preeclampsia translating into substantial cost savings for UK health care payers.
PCV54 EXAMINING THE COST IMPACTS OF RECONFIGURING TIA CARE IN SPAIN
Jackson D 1 , Moshinsky J 2 , Begg A 2 1 GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK, 2 Medaxial Group, London, UK OBJECTIVES: Due to lack of awareness of Transient Ischaemic Attack (TIA) symptoms, many patients may not immediately seek medical help, creating delay in access to treatment. The UK EXPRESS study by Rothwell et al. (Lancet 2007; 370:1432-42) demonstrated that a greater focus on rapid assessment and management of TIA could significantly reduce subsequent stroke rates. With nearly 35,000 cerebrovascular disease-related deaths in Spain last year, we wanted to examine how a shift in care pathways towards that outlined in the EXPRESS study could affect stroke rates, and explore the financial implications of such a shift in care pathway. METHODS:
We developed an economic model to estimate the costs and savings associated with establishing a rapid assessment and treatment clinic for patients with suspected TIA in Spain, in line with phase 2 of the EXPRESS study. We used a population y. We used a population We used a population of 1,000,000 people with an assumed annual incidence of TIA of 0.021%. Current management was based on ESO guidelines and common clinical practice. We included direct costs associated with care (medications, diagnostics and staffwhere data were unavailable, converted UK costs were used), and modeled the ), and modeled the impact of changing management over a three-year time horizon. RESULTS: For an assumed population of 1,000,000, changing the care pathway care to ensure rapid care to ensure rapid assessment and treatment for TIA patients would result in 66 future stroke events 66 future stroke events avoided over 3 years. As a result, the costs associated with changing the pathway of care for TIA would be partially offset by savings in acute management costs associated in acute management costs associated with stroke. CONCLUSIONS: Our model suggests that implementing a revised TIA care pathway in Spain would reduce the number of TIA-related recurrent strokes, leading to reduced costs associated with acute stoke management. This would partially offset the cost of establishing rapid assessment and treatment clinics for patients experiencing TIA.
PCV55 BUDGET IMPACT ANALYSIS OF DIAGNOSTIC OF UNEXPLAINED AND/ OR RECURRENT SYNCOPE WITH APPLICATION OF IMPLANTABLE LOOP RECORDER
Gwiosda B, Palka I, Karas D, Wladysiuk M, Szmurlo D, Rutkowski J, Plisko R, Rys P HTA Consulting, Krakow, Poland OBJECTIVES: Syncope that remains unexplained after a conventional evaluation is a common and vexing medical problem. Implantable loop recorder (ILR) is a new diagnostic method in diagnosis of recurrent syncope with unexplained etiology (NO). The aim of this analysis was to estimate the impact of ILR reimbursement in NO diagnostics on budget of public payer's in Poland. METHODS: The analysis was performed in 5-year time horizon from the public payer's perspective. Information regarding target population and medical resources was extracted from literature and registry PL-US. Data in the registry PL-US were collected during 2006-2008 in 18 Polish centers. Cost data were obtained from the National Health Fund. In the analysis two scenarios were compared: actual (current situation with ILR reimbursement only in special cases) and prognostic (after ILR reimbursement). In the prognostic scenario two financing options of monitoring of patients after ILR implantation were distinguished-AOS and KAOS. One-way sensitivity analysis were performed for the key input parameters. RESULTS: The number of target population for ILR implantation in Poland is stable, approximately 2370 patients. In actual scenario estimated annual public payer expenditure for NO diagnostics in each year 2010-2014 is approximately 9.00 mPLN, where cost of ILR is 0.25 mPLN. Assuming reimbursement of ILR estimated public payer expenditure for NO diagnostics in option AOS is 9.77 mPLN in year 2010 and 16.76 mPLN in year 2014, where ILR costs is 1.44 mPLN and 11.34 mPLN, respectively. In option KAOS public payer expenditure is 9.86 mPLN in year 2010 and 18.49 mPLN in year 2014, where ILR costs is 1.53 mPLN and 13.07 mPLN, respectively. CONCLUSIONS: Our findings suggest that decision concerning ILR reimbursement should not lead to increase total expenses on the NO diagnostics for public payer more than 0.95 mPLN in year 2010 and 10.00 mPLN in year 2014. In this study we estimated the annual change in disease and side-effects costs associated with the addition of prasugrel to a drug formulary for treatment of those with acute coronary syndrome (ACS) undergoing a percutaneous coronary intervention in a managed care organization with 1,000,000 covered lives. The model compared the annual costs in each of the first three years after addition of prasugrel to the formulary assuming a maximum treatment share of 50% after 1 year. The only alternative treatment was clopidogrel and people already being treated with clopidogrel were not switched to prasugrel. The relative risk of subsequent cardiovascular events and bleeding events for each drug were taken from a head-to-head 15-month clinical trial. The risk of cardiovascular events reverted to the risk of those taking only aspirin for those discontinuing prasugrel or clopidogrel treatment. RESULTS: The estimated numbers of cardiovascular events (bleeding events) after an ACS episode with prasugrel on the formulary in the first three years were 541 (36), 528 (42), and 525 (43) respectively and without prasugrel were 548 (35) in all three years. The annual reductions in disease-and bleeding-related costs in the first 3 years after adding prasugrel to the formulary were estimated to be $141,907, $419,377, and $488,119 respectively. CONCLUSIONS: Using a more effective dual oral antiplatelet regimen is likely to result in lower disease-related costs that are not offset by higher bleeding-related costs. The disease-and bleeding-event cost savings estimated in the model should be included in a comprehensive estimate of the budget impact of adding prasugrel to a formulary.
PCV56

IMPACT OF INCLUDING PRASUGREL ON THE FORMULARY FOR PATIENTS WHO UNDERGO PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROME
PCV57
COSTS OF ATRIAL FIBRILLATION IN SLOVAKIA FROM A PAYER PERSPECTIVE
Bielik J 1 , Tomek D 2 , Visnansky M 3 , Foltan V 4 , Lednar M 5 1 Trencin University, Trencin, Slovak Republic, 2 Slovak Society for Pharmacoeconomics, Bratislava, Slovak Republic, 3 General Health Insurance Company, Bratislava, Slovak Republic, 4 Comenius University, Bratislava, Slovak Republic, 5 sanofi-aventis Pharma Slovakia, s.r.o., Bratislava, Slovak Republic OBJECTIVES: Atrial fibrillation (AF) is frequent cardial disease. The prevalence in Slovak republic is estimated about 1% in adult population. The most potential risk of AF is stroke, Ist incidence is estimated about 2.3% e.g. more than six times as in standard population. The main objective of this study was to determine direct medical costs related to AF and the possible budget impact of new treatment by dronedaron. METHODS: Direct medical costs were evaluated from data collected in 2007 from the General Health Insurance Company, the largest one in Slovakia, covering 55% of 5.4 million inhabitants. The results were recalculated to the total population. The costs were quoted in 2007 prices. RESULTS: The AF costs were a16,685,720; in out-patients care they were a1,384,743; in hospital care they were a12,135,196; in drug consumption they were a2,013,127 and in diagnostic procedures they were a1,152,653. Totally it was 0,556% of total Slovakia health care budget. The cost of treating the patients with stroke was a30,098,891, which is 1.003% of total Slovakia health care budget. Dronedaron is new drug for the treatment of AF. The outcomes from the ATHENA study showed 26% risk reduction of hospitalization and 34% risk reduction of stroke. The dronedaron usage can reduce the health care costs by a2,872,370 per year, i.e. 0.096% from total budget. CONCLUSIONS: The direct costs associated with AF comprise an important part of total health care budget in Slovakia. They signalize the need to establish effective strategies for AF. Clinical outcomes from the ATHENA study adapted to Slovak conditions show the actual potential of dronedaron to be a cost-effective way in reducing AF complications and decreasing health care expenditures.
PCV58 THE DIAGNOSTIC BENEFIT OF STRESS TEST PRIOR TO CARDIAC MULTI-SLICE COMPUTED TOMOGRAPHY IN PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE: CLINIC AND ECONOMIC OUTCOMES FROM THE EMILIA-ROMAGNA MSCT REGISTRY
Berti E, Cipriani F, Negro A, Marino M, De Palma R Emilia Romagna Social & Healthcare Agency, Bologna, Italy OBJECTIVES: Cardiac Multi-Slice Computed Tomography (MSCT) has been demonstrated as a valid diagnostic tool for coronary artery disease (CAD) especially due to its higher comparative accuracy. Consequently, there is mutual agreement on its use following a non-interpretable or equivocal stress-test (exercise, perfusion or stressecho) result; however, its frequent use as first-step investigation contributes to the controversy on which strategy really maximizes patient outcomes. Using data of a regional registry, we investigated the optimal application of MSCT in patients with suspected CAD. METHODS: During 2007, 566 patients with suspected CAD or stable angina underwent MSTC in six different public structures in Emilia-Romagna; after applying exclusion criteria (previous hospitalization for Acute Myocardial Infarction and/or revascularization; MSCT performed in inpatient setting), 350 subjects (209 with and 141 without a previous stress-test result, respectively) were considered eligible. All events of interest, such as death, hospitalizations, diagnostic procedures, visits and cardiovascular drugs utilization were traced for one year. Direct costs were evaluated from the perspective of the Regional Health Service (RHS). RESULTS: Except for hyperlipidemia (p 0.0058) and diuretics consumption (p = 0.006), all baseline characteristics were similar between the two groups. No relevant differences were found in all endpoints except for the average number of cardiovascular-related hospitalizations (0.46 vs. 0.33; p 0.0013), which was significantly lower in the "stresstest MSCT" group. Notably, hospitalizations alone accounted for 90% of total health care expenditures (a1.018.054 for all 350 patients). The sensitivity analysis (based on 5000 bootstrap samples) indicated a mean cost difference of a513 / 22 (CI 95%) and a mean hospitalizations difference of 0.13 / 0.003 in favor of the "stresstest MSCT" strategy (0.46 vs. 0.33; p = 0.66), which showed a probability of being cost effective of 0.86 (WTP a10,000). CONCLUSIONS: Using MSTC after stress-test is likely to reduce the risk of hospitalization and additionally provides good value for money from the perspective of the RHS.
PCV59
COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF BETA BLOCKERS FOR CHRONIC HEART FAILURE PATIENTS IN SPAIN
Espallardo O, Polanco C Merck, Madrid, Spain OBJECTIVES: Chronic heart failure (CHF) is a major health issue because of its growing prevalence, morbimortality and associated resource consumption. Beta blockers have been shown to be effective and cost-effective therapies for CHF. The aim is determining what beta blocker constitutes the most efficient therapy for CHF patients in Spain. METHODS: Systematic review of primary (clinical trials) and secondary (meta-analyses, clinical practice guidelines, economic assessments and reports from independent local agencies) evidence on beta blockers for CHF issued before April 2009. Once that efficacy of each beta blocker was established, local drug databases were accessed in order to estimate the updated annual cost of each therapy and daily dose in Spain. RESULTS: Given their similar efficacy [death RR: bisoprolol: 0.66, p 0.0001; metoprolol: 0.66, p 0.0001; carvedilol: 0.65, p 0.005, nebivolol: 0.88, p 0.21] and safety profiles, international clinical guidelines on Cardiology recommend bisoprolol, metoprolol, carvedilol and nebivolol as first choice therapies for CHF (class I and level of evidence A). Significant annual drug cost differences for bisoprolol have been previously reported by independent Spanish agency GENESIS and are confirmed with 2009 prices [bisoprolol: a22. 36-114.58; metoprolol: a30.20-241.63; carvedilol: a39.24-264.62; nebivolol: a52.50-420.01] . When hospitalization costs are included, a recent meta-analysis of beta blockers for CHF in Spain proved that bisoprolol is not only the cheapest beta blocker therapy but even a more efficient alternative than placebo [2005 prices: bisoprolol: a414.28; metoprolol: a507.64; carvedilol: a888.50; placebo: a484.96]. Budget impact analysis yields that bisoprolol implies a saving of 26-53% of metoprolol cost of therapy per year and patient, 43-57% when compared to carvedilol and 57-73% versus nebivolol. CONCLUSIONS: According to recently updated Cardiology guidelines and evidence issued by independent bodies, bisoprolol gathers pharmacologic, legal and pharmacoeconomic characteristics that confirm their being the most efficient beta blocker (both in terms of cost-benefit and cost-effectiveness) for CHF patients in Spain. For patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention, 12-month dual antiplatelet (thienopyridine plus aspirin) treatment is recommended. A phase III clinical trial (TRITON) in ACS patients with planned PCI demonstrated superiority of prasugrel versus clopidogrel on the primary composite endpoint (myocardial infarction, stroke, cardiovascular death) but also higher bleeding risk. This model was designed to estimate the impact on the hospital budget of the national health insurance of substituting prasugrel to clopidogrel. METHODS: The budget impact model was based on index and recurrent hospital stays related to cardiovascular and bleeding causes from the economic cohort of TRITON (N 6705) with a mean of 380 days of follow-up. A specific DRG code was attributed to each stay and transcoded to French DRG. A weighted cost was calculated based on public and private French DRG official tariff (2007), including an average cost for stents and intensive care unit costs. In-hospital costs of thyenopyridine use were not included in the analysis. The time horizon was 1-year. Budget impacts were calculated for two groups: A) Patients without history of transient ischemic attack (TIA) and stroke), B) Patients without TIA/stroke and weight 60 kg and 75 years-old. RESULTS: For Group A the costs for all patients for one year were a25,719,447.48 for prasugrel and a26,123,027.37 for clopidogrel, for Group B they were respectively a20,897,133.23a and a21,096,756.42. Predominant differences were on costs related to recurrent hospital stays (respectively for A: a5,501,347.76 and a6, 053,118.09a; B: 4,354,983.17 and 4,827,315.74) . Substituting prasugrel to clopidogrel would result in daily savings of: A) a0.45 per patient B) 0.46a per patient. CONCLUSIONS: This budget impact model showed that prevention of recurrent events with prasugrel generates savings that could offset to some extent potential price differences with clopidogrel. The HF-ACTION study was a controlled trial to evaluate efficacy and safety of exercise training in patients with heart failure. A prospective economic evaluation was planned alongside the trial to evaluate resource use and costs associated with exercise training. METHODS: Between April 2003 and February 2007, HF-ACTION randomized 2331 heart failure patients with NYHA Class II to IV to usual care plus exercise training, consisting of 36 supervised sessions followed by homebased training, versus usual care alone. Data on medical resource use and hospital bills were collected throughout the trial. Intervention-related costs were estimated using patient-level data from the trial, administrative records, and published unit costs. Counts of resource use were compared using negative binomial regression models. Confidence intervals for cost differences were derived using nonparametric bootstrapping. RESULTS: Mean follow-up was 2.5 years in both groups. There were 2297 hospitalizations in the exercise training group (n 1159) and 2332 in the usual care group (n 1172)(P 0.924). The mean number of inpatient days was 13.6 (SD 27.0) and15.0 (SD 31.4) days in the exercise training and usual care groups, respectively (P 0.21). Additional measures of medical resource use, including urgent care visits, outpatient visits and procedures, home IV therapy, skilled nursing and rehabilitative care were similar between groups, with the exception that fewer patients in the exercise training group underwent high-cost inpatient procedures including heart transplant and/or placement of a left ventricular assist device (n 44 [3.7%] vs. n 31 [2.7%], P 0.14). Total direct medical costs were estimated at $50,857 (SD 81, 488) in the exercise training group and $56,177 (SD 92, 749) in the usual care group (95% CI for difference: $ 12,755 to $1547). Direct cost of exercise training was estimated at $1006 (SD 337). CONCLUSIONS: Exercise training had little systematic impact on medical resource use overall, but the cost of exercise training may have been offset through a reduction in high-cost procedures.
PCV60 BUDGET IMPACT MODEL FOR DETERMINING THE HOSPITAL COSTS OF INTRODUCING PRASUGREL FOR THE LONG TERM TREATMENT OF ACUTE CORONARY SYNDROME TREATED BY PERCUTANEOUS CORONARY INTERVENTION IN FRANCE
PCV61
COST OF EXERCISE TRAINING AND ITS IMPACT ON MEDICAL RESOURCE USE AND COSTS: RESULTS OF HF-ACTION TRIAL
